Introduction
Children hospitalized with end-stage heart failure have among the highest mortality and longest lengths of stay of any condition in paediatrics. 1, 2 Although reasons for this are unclear, there has long been a controversy within the paediatric cardiology community as to the best treatment strategies for children with heart failure-specifically whether the signs, symptoms and outcomes of children with end-stage heart failure are associated primarily with low cardiac output or venous congestion. This controversy often manifests as conflicting treatment recommendations among providers as to whether the primary focus of heart failure therapy should be to increase cardiac output-by increasing cardiac preload to enhance contractility via the Starling mechanism-or to decrease cardiac preload with diuretics, which critics contend could compromise cardiac output. Although once considered controversial, it is now well established that congestion accounts for most of the signs, symptoms and outcomes in adult heart failure patients. Thus, relief of congestion has become the primary focus of contemporary adult heart failure therapy. [3] [4] [5] [6] [7] [8] By contrast, relatively little is known about the haemodynamic profiles of children with end-stage heart failure where the cardiac diagnoses leading to heart failure are different and the signs and symptoms of fluid overload can be quite subtle. 1, 2 Previous work in children with dilated cardiomyopathy (DCM) suggests congestion is more common than low cardiac output and that low cardiac output is primarily associated with outcome. 9 However, that study was limited to the minority of children with DCM, the use of a relatively low pulmonary capillary wedge pressure (PCWP) to define congestion (15 mmHg) , and by a lack of power due to the low event rate typical for this population. 9 Moreover, the analysis did not examine other correlates of heart failure severity such as symptoms and end-organ dysfunction, which could provide a broader context within which to understand the role of haemodynamics in children with end-stage heart failure. Thus, the specific aims of this study are (i) to determine the prevalence of congestion and low cardiac output in children with end-stage heart failure due to a wide range of congenital and acquired cardiac lesions, and (ii) to determine whether congestion or low cardiac output is primarily associated with (a) heart failure symptoms, (b) endorgan dysfunction, and (c) clinical outcome. The broader purpose of this study is to clarify the predominant physiology of children with advanced heart failure to inform heart failure management decisions that can ultimately improve patient symptoms and outcomes.
Methods

Patient cohort
Using the Pediatric Heart Transplant Study (PHTS) database, we identified all children <18 years of age listed for heart transplantation with a cardiac catheterization available between 1993 and 2013. The PHTS is an event-driven prospective international registry of paediatric transplant recipients from 54 centres at the time the analysis was performed. Details of the data registry have been previously published. 10 
Study hypothesis, primary endpoint, and definitions
The primary study hypothesis was that congestion is more common than low cardiac output in children with end-stage heart failure listed for heart transplant. Secondary hypotheses were that congestion is more strongly associated with heart failure symptoms, renal and hepatic dysfunction, and clinical outcome, than low cardiac output. Pulmonary venous congestion and severe pulmonary venous congestion ('wet') were defined as a PCWP >15 and >22 mmHg, respectively, based on published adult definitions, 4, 5, 8, 12 and the definition proposed by Singh et al. 9 Systemic venous congestion and severe systemic venous congestion were defined as RAP >8 and >15 mmHg, respectively. 13 Similarly, low cardiac output ('cold') was defined as CI <2.2 L/min/m 2 . 5,9,12,14 Death or clinical deterioration was defined as death on the waitlist, or an escalation of invasive haemodynamic support at time of transplant by at least one level (oral therapy < inotropes < ventricular assist device or ventilator support < extracorporeal membrane oxygenation, ECMO), categories known to be associated with survival. 15 Severe renal dysfunction was defined as a glomerular filtration rate (GFR) <5th percentile for age as estimated by the modified Schwartz formula, or dialysis. [16] [17] Normal renal function was defined as a normal GFR for age, and mild-moderate dysfunction as all GFR values in-between. 17 Severe hepatic dysfunction was defined as a serum total bilirubin > _1.2 mg/dL, whereas mild to moderate dysfunction were defined as a total bilirubin 0.7 to <1.2 mg/dL, and normal as total bilirubin < _0.7 mg/dL. 17 Heart failure symptoms were defined based on New York Heart Association (NYHA) and/or Ross Infant Heart Failure Classification as reported by centres to PHTS (Supplementary material online, Table S1 ). 18, 19 All variables were defined at the time of listing for heart transplant, including cardiac catheterization data, unless otherwise specified. 
Statistical analysis
Results
The study cohort
Of 2095 patients in the PHTS database with any haemodynamic data at time of listing, 1093 had complete haemodynamic data (with RAP, PCWP, and CI). Thirty-four patients were excluded because of a missing cardiac diagnosis, leaving 1059 patients for the primary study cohort. Patients who were excluded because of incomplete haemodynamic data were younger (median 3.0 years vs. 6.9 years, P < 0.001), smaller (12.1 kg vs. 20 .1 kg, P < 0.001), had more single ventricular congenital heart disease (46% vs. 19%, P < 0.001), more ventilator (24% vs. 15%, P < 0.001), or ECMO (7% vs. 3%, P < 0.001) use at time of listing, and more were listed in an earlier era (1993-2002) (60% were vs. 39%, P < 0.001). The median age of patients was 6.9 years, the median weight was 20 kg, 46% had DCM, 35% had congenital heart disease (including 19% with single ventricle heart disease), 66% were hospitalized, 63% were listed status 1A, 15% were on ventilator support, 3% were on ECMO, 28% had renal dysfunction, and 23% had severe hepatic dysfunction.
Haemodynamics at listing
The haemodynamic variables at listing for the study cohort are summarized in Table 2 . Among all 1059 patients, median CI was 2. . In contrast, 58% had pulmonary venous congestion (PCWP > 15 mmHg), 28% severe pulmonary venous congestion (PCWP > 22 mmHg), 54% systemic venous congestion (RAP > 8 mmHg), and 18% severe systemic venous congestion (RAP > 15 mmHg). Figure 1 shows the prevalence of each haemodynamic profile.
New York Heart Association/Ross classification and end organ dysfunction 
NYHA/Ross classification was most strongly associated with PCWP >22 mmHg (OR 1.9, 95% CI 1.2-3.1, P = 0.006) and was not associated with CI or RAP. Twenty-eight per cent of the study cohort had renal dysfunction and 23% had severe hepatic dysfunction. Renal dysfunction was associated with RAP >15 mmHg (OR 1.7, 95% CI 1.1-2.7, P = 0.009), and with CI when analysed as a continuous variable (OR 0.84, 95% CI 0.71-0.99, P = 0.04) but not as a dichotomous variable. Hepatic dysfunction was associated with RAP > 8 mmHg (OR 1.6, 95% CI 1.1-2.4, P = 0.004), RAP > 15 mmHg (OR 3.2, 95% CI 2.1-4.7, P < 0.001) and to a lesser extent with PCWP > 15 mmHg (OR 1.4, 95% CI 1.0-2.1, P = 0.03), and PCWP > 22 mmHg (OR 1.9, 95% CI 1.3-2.8, P < 0.001). There were no associations between heart failure symptom classification or end-organ dysfunction and low cardiac output (CI < 2.2 L/min/m 2 ).
Death or clinical deterioration
Competing outcomes for the study cohort is shown in Figure 2 . Overall, 821 (78%) patients were transplanted after a median 1.4 (0.5-3.2) months on the waitlist. Ninety-one patients (9%) died on the waitlist at a median 3.6 (1.1-30.1) months, and 129 (12%) had clinical deterioration at time of transplant, totaling 220 (21%) patients who reached the primary study endpoint of death or clinical deterioration. Table 4 summarizes the associations between haemodynamics and death or clinical deterioration. In multivariable analysis, PCWP >22 mmHg was associated with the highest risk of death or clinical deterioration (OR 1.6, 95% CI 1.1-2.4, P = 0.02). There was no association between CI and death or clinical deterioration; however, when low cardiac output (CI < 2.2 L/min/m 2 ) was combined with a PCWP >22 mmHg (a wet and cold profile), the relative risk of death or clinical deterioration was the highest (OR 1.9, 95% CI 1.1-3.5, P = 0.03) ( Figure 3A) . The results for the wet/cold profile were similar regardless of whether children had cardiomyopathy (n = 687, HR 2.5, 95% CI 1.6-3.9, P < 0.001) or congenital heart disease (n = 372, HR 2.6, 95% CI 1.2-5.8, P = 0.02) ( Figure 3B , C).
Children with single ventricle heart disease
Because children with single ventricle heart disease represent a unique subset of patients where the systemic venous pressure (RAP) is typically higher than the pulmonary venous pressure (PCWP), we performed a secondary analysis to examine the association between haemodynamic profiles and clinical manifestations of heart failure in this cohort. Overall, there were 206 (19%) patients with single ventricle heart disease. Median age was 2.5 (0.5-7.5) years, 134 (65%) had HLHS, 78 (38%) were palliated to Glenn and 62 (30%) to Fontan. Systemic venous congestion, defined as RAP >15 mmHg, was 
Other cardiac diagnoses
Given the role that pulmonary and systemic congestion plays in heart failure symptoms, end-organ function, and outcome, we examined the cardiac diagnoses with the highest prevalence of severe pulmonary and systemic venous congestion ( Figure 4) . Dilated cardiomyopathy, myocarditis, and transposition of the great arteries were the leading diagnoses in patients with severe pulmonary venous congestion, whereas tetralogy of Fallot, restrictive cardiomyopathy, and single ventricle heart disease were the most common conditions in patients with severe systemic venous congestion. Atrioventricular septal defect was the cardiac diagnosis with the highest prevalence of combined pulmonary and systemic venous congestion in children with advanced heart failure.
Discussion
In this study, we found that (i) congestion is significantly more common than low cardiac output in children with end-stage heart failure listed for heart transplant, (ii) the severity of heart failure symptoms based on NYHA/Ross classification correlates best with elevations in PCWP, (iii) end-organ dysfunction correlates best with elevations in RAP, and (iv) death or deterioration on the waitlist is highest among children with both congestion and low cardiac output. Our findings are consistent with previous studies by Norhria, Stevenson, and others demonstrating that congestion is more prevalent than low cardiac output in advanced heart failure patients, and that congestion, augmented by decreased cardiac output, is an important risk factor for mortality. [3] [4] [5] [7] [8] In the largest paediatric study performed to date, Singh et al. 9 examined 476 children with idiopathic DCM and found that low cardiac output, but not congestion, was associated with death or de-listing due to clinical deterioration. It is unclear why the findings of the present study differ from this analysis. It may relate to differences in how congestion was defined in the two studies (a PCWP >15 mmHg in the Singh study vs. >22 mmHg in the present study) altering specificity. Indeed, secondary analyses of the DCM cohort suggested that a PCWP >22 mmHg performed better at discriminating clinical outcomes. Other possibilities include that the DCM cohort was restricted to patients with systolic dysfunction, reduced statistical power because of the low event rate (6.7%) and smaller cohort, or a lower prevalence of congestion in the DCM cohort because patients on mechanical circulatory support and/or mechanical ventilation were excluded. 9 In contrast, the present study, which analyses over 1000 children with advanced heart failure, includes children listed for transplant for all forms of underlying cardiac disease, is one of the largest and most comprehensive study to date on the role of haemodynamics in paediatric heart failure. This is also the first study to demonstrate that (i) both congestion and cardiac output hold important prognostic value in children with advanced heart failure, (ii) the severity of heart failure symptoms in children is associated primarily with congestion, (iii) end-organ dysfunction appears to be more strongly associated with congestion than cardiac output, and (iv) the major causes of left and right heart failure in paediatrics vary significantly by cardiac diagnosis.
Another major finding of this study is that renal dysfunction appears to be most strongly associated with an elevated RAP. As a retrospective and observational study, we are unable to conclude whether this association was due to renal dysfunction causing fluid overload or venous congestion worsening renal function. However, our finding of an association between elevated RAP and renal dysfunction is consistent with work by Mullens et al. 3 suggesting that venous congestion is the most important factor associated with worsening renal function in adult advanced heart failure patients. Tunuguntla et al. 20 at Texas Children's Hospital also recently reported a similar finding in a cohort of 322 children with cardiovascular disease. This observation is important because it suggests that untreated residual systemic venous congestion is not without some risk. Indeed, the haemodynamic profile of warm/dry was found to be the profile in the present study with the lowest prevalence of endorgan dysfunction. Unfortunately, while adjusting diuretic therapy to normalize the jugular venous pressure can be carried out with relative ease in adult heart failure patients, 21 this can be more difficult to estimate reliably in children. We also found that, similar to adults, the severity of heart failure symptoms was more strongly associated with the degree of congestion than with low cardiac output. This suggests that, also similar to adults, relief of congestion may result in relief of heart failure symptoms, such as abdominal pain, fatigue, and shortness of breath, more so than attempts to augment cardiac output. Historically, early theories of heart failure understood that the signs and symptoms of heart failure were caused by 'forward pump failure' (e.g. abdominal pain attributed to mesenteric ischaemia). While forward pump failure is a major problem in critically ill patients, more contemporary studies in large cohorts of NYHA class III and IV adult patients showed that treating congestion, independent of cardiac output, resulted in effective relief of heart failure symptoms and improved survival. 12, 14, 22 Moreover, clinical trials of agents intended to improve cardiac output specifically, such as beta-adrenergic agonists, resulted paradoxically in higher mortality and were abandoned as routine therapy.
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Figure 2 Competing risks curve depicting probability of transplant, death, removal from the waitlist, and survival on the waitlist.
Haemodynamic profiles in paediatric heart failure .
This study has several important implications. First, our findings suggest that similar to adult practice venous congestion may play a greater role in the signs, symptoms and outcomes of paediatric advanced heart failure than previously believed. Indeed, while our study suggests congestion is common, a growing number of reports suggest congestion may be surprisingly difficult to recognize clinically in children, even at first hospitalization. 25 Hollander et al. 25 reported that fewer than 10% of children presenting with new onset heart failure manifested signs of fluid overload to paediatric heart failure cardiologists. In the Canadian Pediatric Heart Failure Guidelines published in 2013, Kantor et al. 26 emphasized that pedal oedema, facial oedema, and ascites are notably uncommon in paediatric heart failure patients.
It is not entirely clear why venous congestion may be harder to recognize clinically in children compared to adults, but several factors may contribute: (i) Unlike adults, in children extracellular fluid tends not to pool in obvious places like the ankles, where it is readily visible to families and providers; (ii) family members may misattribute the telltale signs of fluid overload in adults-such as sudden weight gain or outgrowing shoes and clothes-to normal somatic growth in children; and (iii) jugular venous distension-arguably the most important exam finding used to adjudicate volume status in adults-can be surprisingly difficult to interpret reliably in infants and children.
Second, our findings also suggest that invasive haemodynamic data may have a greater role to play in children with advanced heart failure . Diagnoses are not mutually exclusive and 98 patients had > _2 diagnoses. Single V, single ventricle; Pulm Atresia, pulmonary atresia; RCM, restrictive cardiomyopathy; HCM, hypertrophic cardiomyopathy; VSD, ventricular septal defect; CCTGA, congenitally corrected transposition of the great arteries; TOF, tetralogy of Fallot; DCM, dilated cardiomyopathy. than in adults. Because of the reliability of the bedside physical exam in adult patients, invasive haemodynamic monitoring has been found to add little information in most adult heart failure patients. However, this may be less true in children, where the clinical assessment of filling pressures is less reliable. Non-invasive methods of estimating filling pressures-such as with natriuretic peptides or echocardiographic indices-have been assessed in adult studies, but such methods warrant further investigation in the paediatric heart failure population. Cardiac catheterization may provide the most accurate data on filling pressures but because the risks of cardiac catheterization in children may be higher than adults due to the need for sedation, the risk of obtaining invasive data must be weighed carefully against its anticipated benefit.
Lastly, our findings raise the possibility that haemodynamic parameters themselves may be useful surrogate endpoints for clinical trials to evaluate advanced cardiac treatment in children. The field of paediatric heart failure is significantly lacking in FDA-approved therapies. The population of paediatric heart failure patients is magnitudes smaller than adult heart failure patients. As a result, clinical trials with endpoints such as transplant or mortality are not feasible simply due to lack of adequate sample size. Surrogate endpoints are sorely needed in paediatric heart failure. Our finding of associations between haemodynamic parameters and heart failure signs, symptoms, and outcomes suggests that haemodynamics may be considered as potential surrogate endpoints for clinical trials. Application of this principle has been illustrated by the Sildenafil Use in Pulmonary Arterial Hypertenstion (SUPER) study, where a reduction in the mean pulmonary arterial pressure led to FDA approval of sildenafil for pulmonary hypertension. 27 Further studies are needed to determine the optimal strategies for leveraging haemodynamic data to support regulatory approval studies in children.
Limitations
This study must be interpreted within the context of the study design. First, it is well known that cardiac catheterization data can be influenced by a variety of factors including sedation level, cardiac support, and physiological assumptions such as the patient's oxygen consumption. Nevertheless, we believe cardiac catheterization data represents the best method available to generate reliable pressure and flow estimates in children, and is therefore widely regarded to be the gold standard despite these known assumptions. Second, this was a retrospective study of registry data where missing or incomplete catheterization data could skew study findings. There is selection bias in that half of the patients in the PHTS database were excluded due to incomplete haemodynamic data. Even though those excluded were a smaller, sicker cohort from an earlier era, nearly a quarter of our study cohort were on a ventilator, VAD or ECMO, and almost 50% of our study cohort was under 5 years of age. We also found it reassuring that both the distribution of haemodynamic values and the primary study findings are highly consistent with previous studies of adults with advanced heart failure, 4, 5, 8 as well as the clinical experience of the individual centres represented on the manuscript. Lastly, while our findings suggest the role of venous congestion and low cardiac output are applicable across a wide range of underlying congenital and acquired forms of heart disease in children, it is possible that the effect is modified in certain diagnoses such as single ventricle disease, as suggested in our secondary analysis. Further research is clearly needed to fully understand the role of haemodynamics in children with single ventricle heart disease, which may vary across each of the three stages of single ventricle palliation.
Conclusion
Venous congestion is more common than low cardiac output in children suffering from severe heart failure, and similar to adult heart failure patients, is associated with more severe heart failure symptoms, end-organ dysfunction, and worse outcome in children. Still, low cardiac output is present in one in five children listed for transplant, and combined with congestion, children with a wet/cold profile had the worst outcomes, consistent with adult heart failure studies. Invasive haemodynamic data, though not without risk, may be more important to obtain in children than adults because of the limitations of the heart failure exam in children. Further research is needed to determine the precise roles of haemodynamic parameters in paediatric heart failure, which remains one of the most lethal conditions in paediatrics.
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